Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Stock Information for Delcath Systems Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Delcath Systems Inc.

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Delcath Systems Reports First Quarter 2026 Results and Business Highlights
Delcath Systems to Host First Quarter 2026 Earnings Call
Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO-EURACAN Clinical Practice Guidelines for Uveal Melanoma
Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting
Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology
Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.